Osaka Soda Co (4046) Q4 2026 earnings summary

Executive summary

• Achieved record-high sales and profits in FY2025, with net sales up 3.7% to ¥99,961 million, operating income up 33.1% to ¥17,634 million, and net income up 49.6% to ¥15,460 million, all record highs.

• Growth was driven by recovery in Basic Chemicals and strong Healthcare demand, while Functional Chemicals and Trading/Others saw declines.

• Business performance improved due to resolution of production issues in Basic Chemicals, favorable market conditions, and Healthcare growth.

• The company completed its medium-term plan and launched a new plan targeting ¥30,000 million operating income by FY2030.

• Net sales missed plan due to delayed recovery in Functional Chemicals, but profitability exceeded expectations.

Financial highlights

• FY2025 net sales: ¥99,961 million (+3.7% YoY); operating income: ¥17,634 million (+33.1% YoY); ordinary income: ¥19,608 million (+38.5% YoY); net income: ¥15,460 million (+49.6% YoY).

• Gross profit increased to ¥33,728 million from ¥28,946 million YoY.

• Comprehensive income more than doubled to ¥20,453 million from ¥9,904 million.

• Earnings per share rose to ¥123.96 from ¥81.54 YoY.

• Overseas sales increased 8.6% YoY to ¥39,308 million.

• Operating cash flow reached a record high of ¥19,875 million.

• Cash and cash equivalents at year-end were ¥48,802 million, up ¥5,488 million YoY.

Outlook and guidance

• FY2026 forecast: net sales ¥106,000 million (+6.0% YoY), operating income ¥19,000 million (+7.7% YoY), ordinary income ¥20,400 million (+4.0% YoY), net income ¥13,600 million (-12.0% YoY).

• Healthcare segment expected to drive profit growth; price revisions planned to offset rising input costs.

• Overseas sales projected to rise 9.9% YoY.

• New medium-term plan focuses on healthcare growth, new business creation, and management foundation strengthening.